Revelation Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, net income was USD 4.71 million compared to net loss of USD 8.45 million a year ago. Basic earnings per share from continuing operations was USD 48.3 compared to basic loss per share from continuing operations of USD 591.3001 a year ago. Diluted earnings per share from continuing operations was USD 45.9 compared to diluted loss per share from continuing operations of USD 591.3001 a year ago.